Day: August 1, 2025

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net sales decreased 25% to $1.15 billion GAAP EPS increased 3% to $12.81; non-GAAP EPS(a) increased 12% to $12.89 FDA approved Lynozyfic™ (linvoseltamab) for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria (CSU) FDA accepted for priority review Libtayo® sBLA for adjuvant cutaneous squamous cell carcinoma (CSCC) In-licensed rights to late-stage dual GLP-1/GIP receptor agonist; reported interim 26-week data from Phase 2 COURAGE trial in obesityTARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals,...

21,017 vehicles were delivered in July 2025 135,167 vehicles were delivered year-to-date in 2025, increasing by 25.2% year-over-year Cumulative deliveries reached 806,731 as of July 31, 2025SHANGHAI, Aug. 01, 2025 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its July 2025 delivery results. The Company delivered 21,017 vehicles in July 2025. The deliveries consisted of 12,675 vehicles from the Company’s premium smart electric vehicle brand NIO, 5,976 vehicles from the Company’s family-oriented smart electric vehicle brand ONVO, and 2,366 vehicles from the Company’s small smart high-end electric car brand FIREFLY. Cumulative deliveries reached 806,731 as of July 31, 2025. Our smart large-space...

Strong second quarter performance reflected disciplined execution and operational excellence Comparing the second quarter of 2025 to the second quarter of 2024:Sales decreased 3% to $10.6 billion, as light vehicle production declined 6% and 2% in North America and Europe, respectively Income from operations before income taxes increased 16% to $496 million Adjusted EBIT increased 1% to $583 million and Adjusted EBIT margin improved 20 basis points to 5.5% Diluted earnings per share of $1.35 and Adjusted diluted earnings per share of $1.44 increased 24% and 7%, respectivelyReturned $324 million to shareholders in dividends and share repurchases in the first half of 2025, including $137 million in dividends during the second quarter Updated 2025 outlook, including increases to Total Sales, Adjusted EBIT Margin, and Adjusted Net Income...

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, and the upsized structure will provide CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the “Loan”).  The Loan comprises tranches 1, 2 and 3, in the amounts of CHF 25.0 million each, as well as an additional loan of up to CHF 25.0 million, which may be made available...

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, and the upsized structure will provide CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the “Loan”). The Loan comprises tranches 1, 2 and 3, in the amounts of CHF 25.0 million each, as well as an additional loan of up to CHF 25.0 million, which may be made available by...

COMPANY ANNOUNCEMENT Odense, August 1st, 2025 Company Announcement no. 62 – 01.08.2025                 Danish Aerospace Company to support development of a new area: 3D Bone Quality Imaging system for space Danish Aerospace Company A/SCVR no.: 12424248 Danish Aerospace Company A/S (DAC), Odense, has signed a subcontract with Adaptix Ltd. of UK to support the development of a ground prototype of a new 3D Bone Quality Imaging System for future use in space. The contract – which Adaptix Ltd. has commenced with the European Space Agency – has potential for a later substantial development contract of a flight system for use in space including on the International Space Station ISS.The 24-month contract entails the development of a prototype of a 3D Bone Quality Imaging system for space based on the Adaptix’ core technology. The prototype...

Paris, August 1st, 2025 Implementation of a New Liquidity Contract Air France-KLM announces the implementation of a liquidity contract for its ordinary shares (ISIN Code: FR001400J770) with Rothschild Martin Maurel, within the framework of the regulations in force, and in particular AMF Decision no. 2021-01 of 22 June 2021. The purpose of this agreement is for Rothschild Martin Maurel to act as a market maker for Air France-KLM shares on the regulated market of Euronext Paris to promote the liquidity of transactions and the regularity of the listing of Air France-KLM shares. To implement this contract, 10 million euros have been allocated to the liquidity account. This contract will take effect on 1 August 2025 and will have an initial term of 12 months, renewable automatically for successive 12-month periods. This agreement may be suspended...